Sharath Hedge

CSO at Congruence Therapeutics

Speaker

Sharath S. Hegde, Ph.D., is Chief Scientific Officer at Congruence Therapeutics who has participated in the discovery of several NCEs including the marketed medicines Vibativ® (telavancin), Yupelri®(revefenancin), Aloxi® (palonosetron) and others in late-stage development including ampreloxetine and REC-3964. He has over 32 years of leadership experience (Roche, Theravance Biopharma, Recursion, Herophilus, Congruence) in strategic and tactical aspects of drug-discovery and early clinical development. He has a sound understanding of integrating computational/AI/ML tools with traditional drug-discovery approaches and has led teams in biotech and techbio companies. He possesses extensive experience in seeding new project ideas and driving the discovery of first-in-class/best-in-class drugs in multiple therapeutic areas. He is the co-author of over 50 scientific publications.